BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28643325)

  • 1. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
    Zhang Q; Yuan XF; Lu Y; Li ZZ; Bao SQ; Zhang XL; Yang YY; Fan DM; Zhang YZ; Wu CX; Guo HX; Zhang YJ; Ye Z; Xiong DS
    Int J Cancer; 2017 Oct; 141(7):1445-1457. PubMed ID: 28643325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice.
    Li Z; Ye Z; Zhang X; Zhang Q; Fan D; Zhang Y; Luo HR; Yuan X; Li Z; Xiong D
    Oncotarget; 2016 Aug; 7(32):51815-51828. PubMed ID: 27322080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
    Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
    Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.
    Yan C; Yang M; Li Z; Li S; Hu X; Fan D; Zhang Y; Wang J; Xiong D
    Biomaterials; 2014 Mar; 35(9):3035-43. PubMed ID: 24406219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.
    Yang Y; Zhang X; Lin F; Xiong M; Fan D; Yuan X; Lu Y; Song Y; Zhang Y; Hao M; Ye Z; Zhang Y; Wang J; Xiong D
    J Hematol Oncol; 2019 Apr; 12(1):46. PubMed ID: 31023384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
    Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
    Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.
    Si S; Sun Y; Li Z; Ge W; Zhang X; Hu P; Huang Y; Chen G; Song H; Huang Y; Ma B; Li X; Sui Y
    Gene Ther; 2006 Nov; 13(22):1603-10. PubMed ID: 16855617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
    Sagawa T; Yamada Y; Takahashi M; Sato Y; Kobune M; Takimoto R; Fukaura J; Iyama S; Sato T; Miyanishi K; Matsunaga T; Takayama T; Kato J; Sasaki K; Hamada H; Niitsu Y
    Hepatology; 2008 Sep; 48(3):828-40. PubMed ID: 18756484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma.
    Hallenbeck PL; Chang YN; Hay C; Golightly D; Stewart D; Lin J; Phipps S; Chiang YL
    Hum Gene Ther; 1999 Jul; 10(10):1721-33. PubMed ID: 10428217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.
    Takahashi M; Sato T; Sagawa T; Lu Y; Sato Y; Iyama S; Yamada Y; Fukaura J; Takahashi S; Miyanishi K; Yamashita T; Sasaki K; Kogawa K; Hamada H; Kato J; Niitsu Y
    Mol Ther; 2002 May; 5(5 Pt 1):627-34. PubMed ID: 11991754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.
    Liu Y; Butterfield LH; Fu X; Song Z; Zhang X; Lu C; Ding G; Wu M
    Int J Oncol; 2011 Jul; 39(1):245-53. PubMed ID: 21491085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.
    Ohashi M; Kanai F; Tateishi K; Taniguchi H; Marignani PA; Yoshida Y; Shiratori Y; Hamada H; Omata M
    Biochem Biophys Res Commun; 2001 Mar; 282(2):529-35. PubMed ID: 11401492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
    Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
    Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.